SCHEMBL2402269

SCHEMBL2402269

N#Cc1ccc(S(=O)(=O)N[C@H]2CC[C@H](C(=O)N3CCN(C4CCC4)CC3)CC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 7/20 0.53
IRAK4 Q9NWZ3 4/20 0.52
THRB P10828 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HRH2 P25021 1/20 0.45
HRH1 P35367 1/20 0.45
KCNH2 Q12809 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HPGD P15428 1/20 0.44
HTT P42858 1/20 0.44
KDM2B Q8NHM5 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2402262 1.00 HRH3 (0.53) HRH3IRAK4THRBALDH1A1HRH2
SCHEMBL2401452 0.98 IRAK4 (0.52) HRH3IRAK4THRBALDH1A1HRH2
SCHEMBL2401449 0.98 IRAK4 (0.52) HRH3IRAK4THRBALDH1A1HRH2
SCHEMBL2400993 0.91 IRAK4 (0.49) HRH3IRAK4THRBALDH1A1HRH2
SCHEMBL2400989 0.91 IRAK4 (0.49) HRH3IRAK4THRBALDH1A1HRH2
SCHEMBL2401122 0.86 ALDH1A1 (0.50) HRH3ALDH1A1HRH1MEN1KMT2A
SCHEMBL2401119 0.86 ALDH1A1 (0.50) HRH3ALDH1A1HRH1MEN1KMT2A
SCHEMBL2404155 0.85 THRB (0.51) IRAK4THRBALDH1A1HRH2HRH1
SCHEMBL2401388 0.84 KMT2A (0.44) HRH3IRAK4ALDH1A1MEN1KMT2A
SCHEMBL2401393 0.84 KMT2A (0.44) HRH3IRAK4ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017773-B2 Cyclohexyl sulfonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2011-09-13 US claimed
EP-1979322-B1 CYCLOHEXYL SULFONAMIDE DERIVATIVES HAVING H3 RECEPTOR ACTIVITY HOFFMANN LA ROCHE (CH) 2010-09-01 EP claimed
US-20100120791-A1 CYCLOHEXYL SULFONAMIDE DERIVATIVES NETTEKOVEN MATTHIAS 2010-05-13 US claimed
US-20070173511-A1 Cyclohexyl sulfonamide derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-07-26 US claimed
US-8017773-B2 Cyclohexyl sulfonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2011-09-13 US disclosed
EP-1979322-B1 CYCLOHEXYL SULFONAMIDE DERIVATIVES HAVING H3 RECEPTOR ACTIVITY HOFFMANN LA ROCHE (CH) 2010-09-01 EP disclosed
US-20100120791-A1 CYCLOHEXYL SULFONAMIDE DERIVATIVES NETTEKOVEN MATTHIAS 2010-05-13 US disclosed
US-20070173511-A1 Cyclohexyl sulfonamide derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120791-A1 CYCLOHEXYL SULFONAMIDE DERIVATIVES HRH3, HRH4, HRH1 HRH3 1/4885IRAK4 1193/4885THRB 325/4885
US-20070173511-A1 Cyclohexyl sulfonamide derivatives HRH3, HRH4, HRH1 HRH3 1/4885IRAK4 1193/4885THRB 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.